RecruitingPhase 4NCT07799493

Caplyta Versus Placebo for Adults With Social Anxiety Disorder

Caplyta® in the Treatment of Social Anxiety Disorder: A Double-Blind Study

Sponsor

Jason Careri

Enrollment

40 participants

Start Date

Sep 10, 2026

Study Type

INTERVENTIONAL

Conditions

Social Anxiety Disorder (SAD)

Summary

The goal of this clinical trial is to learn if Caplyta works to treat Social Anxiety Disorder in adults. The main question it aims to answer is: Does Caplyta lower the frequency/severity of social anxiety symptoms in adults? Researchers will compare Caplyta to a placebo (a look-alike substance that contains no drug) to see if Caplyta works to treat Social Anxiety Disorder. Participants will: Take Caplyta or a placebo every day for 8 weeks Visit the clinic once every week for checkups and tests

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Lumateperone 42 mg and a drug called Placebo for people with social anxiety disorder (sad). The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.